GRPR and neoplasm: The first-generation GRPR-targeting agonists showed some promise but the second-generation antagonists were found to be more beneficial; they not only demonstrated less off-target effects but also a higher tumour uptake, more advantageous pharmacokinetics, and higher tumour-to-background ratios [19,20].